Arterial hypertension and Diabetes: Coexistence of two medical conditions (aspects of pathophysiology and management).

Authors

  • POPESCU Liuba IMSP Institutul de Cardiologie, Clinica “Hipertensiuni arteriale”
  • MOISEEVA Anna IMSP Institutul de Cardiologie, Clinica “Hipertensiuni arteriale”
  • DURNEA Aliona IMSP Institutul de Cardiologie, Clinica “Hipertensiuni arteriale”
  • CARAUȘ Alexandru IMSP Institutul de Cardiologie, Clinica “Hipertensiuni arteriale”

DOI:

https://doi.org/10.52692/1857-0011.2022.1-72.19

Keywords:

arterial hypertension, mellitus diabetes, diagnosis, treatment

Abstract

Hypertension and diabetes are two cardiovascular diseases which frequently coexistence, are high prevalence is likely to continue increasing considerably, influences on increasing of global cardiovascular risk and results with important clinical and social determinants. Treatment goals can be individualized in a stepwise approach, including lifestyle modification, psychosocial factors, risk factor treatment, and social determinants, targets and goals for LDL-C, BP, and glycaemic control.

Author Biographies

POPESCU Liuba, IMSP Institutul de Cardiologie, Clinica “Hipertensiuni arteriale”

dr. in șt. med., conf. cercetător

MOISEEVA Anna, IMSP Institutul de Cardiologie, Clinica “Hipertensiuni arteriale”

dr. in șt. med., cercetător stiințific

DURNEA Aliona, IMSP Institutul de Cardiologie, Clinica “Hipertensiuni arteriale”

dr. in șt. med., cercetător stiințific

CARAUȘ Alexandru, IMSP Institutul de Cardiologie, Clinica “Hipertensiuni arteriale”

dr. hab șt. med., profesor cercetător

References

IDF Clinical Guidelines Task Force. Global Guideline for Type 2 Diabetes. http://societate-diabet.ro/pdf/Global-Guideline-for-Type-2-Diabetes-IDF-2012.pdf.2012

Mancia G, Fagard R, Narkiewicz K et al. ESH/ESC Guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens.2013; 31:1281-1357.

Bakris GL, Sowers JR, Glies TD, et al. Treatment of hypertension in patients with diabetes an update. J Am Soc Hypertens. 2010;4:62-7.

Ferrannini E, Cushman WC. Diabetes and hypertension: the bad companions. Lancet. 2012; 11;380 (9841): 601-10.

Rhys Williams, Stephen Colagiuri, Reem Almutairi et al. International Diabetes Federation IDF DIABETES ATLAS Ninth edition 2019. www.idf.org/our-activities/world-diabetes-day/2018-19-theme.html și http://www.diabetesatlas.org/

Williams, B., Poulter, N.R., Brown, M.J., et al., British Hypertension Society guidelines for hypertension management 2004 (BHS-IV): summary. BMJ, 2004; 328(7440): p. 634-640. 27.

Bryan Williams, Giuseppe Mancia et all. 2018 ESC/ ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH).

Francesco Cosentino, Peter J. Grant, Victor Aboyans et al. Ghidul ESC 2019 de diabet, pre-diabet, şi boli cardiovasculare realizat în colaborare cu Asociaţia Europeană de Studiu a Diabetului (EASD). Romanian Journal of Cardiology | 2019;Vol. 29, No. 4,.

American Diabetes Association. Cardiovascular Disease and Risk management. Diabetes Care 2019; 42 (Suppl 1): S103-S123.

Chen G, McAlister F, Walker R, et al. Cardiovascular outcomes in Framingham participants with diabetes: the importance of blood pressure. Hypertension. 2011;57(5):891-7.

Muniyappa R, Montagnani M, Koh KK. Cardiovascular actions of insulin. Endocr Rev. 2007;28 (5):463-91.

Sarafidis PA, Lasaridis AN. Actions of peroxisome proliferator-activated receptors-gamma agonists explaining a possible blood pressure-lowering effect. Am J Hypertens 2006;19 (6:646-53.)

Bender SB, McGraw AP, Jaffe IZ. Mineralocorticoid receptor-mediated vascular insulin resistance: an early contributor to diabetes-related vascular disease? Diabetes. 2013;62(2):313-9.

Takeda K, Ichiki T, Tokunou T, Funakoshi Y, Iino N, Hirano K, Kanaide H, and Takeshita A. Peroxisome proliferator-activated receptor gamma activators downregulate angiotensin II type 1 receptor in vascular smooth muscle cells. Circulation 2000;102(350):1834–1839,.

Hermida RC, Ayala De, Mojon A. Influence of time of day of blood pressure-lowering treatment on cardiovascular risk in hypertensive patients with type 2 diabetes. Diabetes Care. 2011;34 (6):1270-6.

Frank L.J. Visseren, Francois Mach, Yvo M. Smulders. ESC Guidelines on cardiovascular disease prevention in clinical practice. 2021; p.3281-3290.

Paul A. James, MD; Suzanne Oparil, MD; Barry L. Carter et al. Evidence-Based Guideline for the Management of High Blood Pressure in Adults Report From the Panel Members Appointed to the Eighth Joint National Committee (JNC 8). 2014.

Slater TA, Patel PA. Diabetes Care for the General Cardiologist: A Summary of EMPA-REG and LEADER trials. J Cardiol Clin Res. 2018; 6(2):1134.

Cooney MT, Dudina A, Whincup P et all.; SCORE Investigators. Re-evaluating the Rose approach: comparative benefits of the population and high-risk preventive strategies. Eur J Cardiovasc Prev Rehabil. 2009;16:541549.

Published

2022-04-08